CD13 as a Potential Membrane Marker in PSMA-Negative Prostate Cancer: A Complementary or Superior Alternative to PSMA

被引：0
|
作者：
Tang, Y. [1 ,2 ]
Xiao, L. [1 ]
Yang, J. [1 ]
Hou, J. [1 ]
Hong, J. [2 ]
Rominger, A. [2 ]
Shi, K. [2 ]
Hu, S. [1 ]
机构：
[1] Cent South Univ, Xiangya Hosp, Changsha, Peoples R China
[2] Bern Univ Hosp, Inselspital, Dept Nucl Med, Bern, Switzerland
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2024年 / 51卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OP-424
引用
收藏
页码：S195 / S195
页数：1
相关论文
共 42 条
  • [1] CD13 as a potential membrane marker in PSMA-negative prostate cancer and first-in-human study of [18F]AlF-CD13-L1 PET/CT imaging
    Tang, W.
    Zhou, M.
    Lu, C.
    Qi, L.
    Zhang, Y.
    Tang, Y.
    Gao, X.
    Hu, S.
    Cai, Y.
    ANNALS OF ONCOLOGY, 2024, 35
  • [2] FAP is a Potential Theranostic Target for PSMA-negative Castration Resistant Prostate Cancer
    Zuo, Chunlai
    Huang, RongRong
    Mona, Christine
    Lotan, Tamara
    True, Lawrence
    Morrissey, Colm
    Czernin, Johannes
    Calais, Jeremie
    Magyar, Clara
    Ye, Huihui
    LABORATORY INVESTIGATION, 2021, 101 (SUPPL 1) : 637 - 638
  • [3] FAP is a Potential Theranostic Target for PSMA-negative Castration Resistant Prostate Cancer
    Zuo, Chunlai
    Huang, RongRong
    Mona, Christine
    Lotan, Tamara
    True, Lawrence
    Morrissey, Colm
    Czernin, Johannes
    Calais, Jeremie
    Magyar, Clara
    Ye, Huihui
    MODERN PATHOLOGY, 2021, 34 (SUPPL 2) : 637 - 638
  • [4] ImmunoPET imaging of Trop2 for PSMA-Negative Prostate Cancer
    Long, X.
    Wei, W.
    Lan, X.
    Jiang, D.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S447 - S447
  • [5] PSMA-negative prostate cancer and the continued value of choline-PET/CT
    Alberts, Ian
    Sachpekidis, Christos
    Fech, Viktor
    Rominger, Axel
    Afshar-Oromieh, Ali
    NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2020, 59 (01): : 33 - 34
  • [6] SABRE: Assessment of safety and efficacy of 64Cu-SAR-BBN in PSMA-negative biochemical recurrent prostate cancer patients
    Nordquist, Luke
    Lengyelova, Eva
    Iagaru, Andrei
    Mancini, Brandon
    Song, Hong
    Osman, Medhat
    Josephson, David
    Almaguel, Frankis
    Saltzstein, Daniel
    Parker, Michelle
    Miller, Robert
    Shore, Neal
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65
  • [7] Nomogram to predict the presence of PSMA-negative but FDG-positive lesion in castration-resistant prostate cancer: a multicenter cohort study
    Pan, Jian
    Zhang, Tingwei
    Chen, Shouzhen
    Bu, Ting
    Zhao, Jinou
    Ni, Xudong
    Shi, Benkang
    Gan, Hualei
    Wei, Yu
    Wang, Qifeng
    Wang, Beihe
    Wu, Junlong
    Song, Shaoli
    Wang, Feng
    Liu, Chang
    Ye, Dingwei
    Zhu, Yao
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
  • [8] SABRE: Assessment of safety and efficacy of 64Cu-SAR-BBN in patients with PSMA-negative biochemical recurrent prostate cancer.
    Lengyelova, Eva
    Iagaru, Andrei
    Mancini, Brandon Robert
    Song, Hong
    Osman, Medhat
    Josephson, David
    Almaguel, Frankis
    Saltzstein, Daniel
    Parker, Michelle
    Miller, Robert M.
    Shore, Neal D.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : TPS346 - TPS346
  • [9] Development of a 18F-Labeled Bicyclic Peptide Targeting EphA2 for Molecular Imaging of PSMA-Negative Prostate Cancer
    Gan, Qianqian
    Cui, Kai
    Cao, Qi
    Zhang, Ning
    Yang, Min-Fu
    Yang, Xing
    JOURNAL OF MEDICINAL CHEMISTRY, 2023, 66 (21) : 14623 - 14632
  • [10] In vitro investigation of a potential complementary expression of the imaging biomarkers AR and PSMA during prostate cancer progression
    Balber, T.
    Raitanen, J.
    Bencurova, K.
    Franssen, T.
    Schwarzl, P.
    Kalla, J.
    Culig, Z.
    Hacker, M.
    Egger, G.
    Mitterhauser, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S329 - S330
12345